Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Q3 2026 data is still coming in (13F filing deadline: Nov 16, 2026), so these numbers are incomplete.
Q3 2026 vs. Q2 2026
How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q2 2026 and Q3 2026.
All holders in Q3 2026All holders in Q2 2026
| Measure | Q2 2026 | Of which not filed for Q3 2026 | Q3 2026 | Change |
|---|---|---|---|---|
| Holders | 131 | 130 | 1 | 0 |
| Shares | 116.5M | 109.9M | 6.65M | +50.0K (+0.8%) |
| Value | $152.7M | $144.0M | $6.35M | −$2.29M (−26.5%) |
130 institutions that held it in Q2 2026 haven't filed for Q3 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (0)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q3 2026 but not at the end of Q2 2026.
None.
Sold out (0)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q2 2026 and filed for Q3 2026 without it.
None.
Not filed for Q3 2026 yet (130)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q2 2026 and haven't filed a 13F for Q3 2026. Not filing isn't selling, so they aren't counted as sold out.
Showing the largest 100 of 130 by value.